论文部分内容阅读
为了探讨尿液纤维连接蛋白（Ｆｎ）与膀胱癌生物学行为的关系，采用ＥＬＩＳＡ法检测５０例膀胱癌、３０例其他泌尿生殖系疾病患者及２０例正常人的尿液Ｆｎ含量。结果发现：膀胱癌病人尿液Ｆｎ含量为０．６８±０．４９μｇ／μｍｏｌＣｒ，明显高于正常人０．１０±０．０４μｇ／μｍｏｌＣｒ及其他泌尿生殖系疾病患者的０．２０±０．１０μｇ／μｍｏｌＣｒ。尿Ｆｎ与肿瘤分期分级也有关。膀胱癌病人术后尿液Ｆｎ为０．２１±０．１１μｇ／μｍｏｌＣｒ，明显下降。提示尿液Ｆｎ含量可作为膀胱癌的诊断、估计预后及疗效监测的指标。
In order to investigate the relationship between urinary fibronectin (Fn) and biological behavior of bladder cancer, urinary Fn levels in 50 cases of bladder cancer, 30 cases of other genitourinary diseases and 20 cases of normal people were detected by ELISA. The results showed that urinary Fn content of bladder cancer patients was 0.68 ± 0.49μg / μmolCr, which was significantly higher than that of normal persons 0.10 ± 0.04μg / μmolCr and other patients with genitourinary tract 0.20 ± 0.10μg / ΜmolCr. Urinary Fn is also related to staging of tumors. Postoperative urine Fn was 0.21 ± 0.11μg / μmolCr in bladder cancer patients, significantly decreased. Tip urine Fn content can be used as bladder cancer diagnosis, prognosis and efficacy monitoring indicators.